Corticosteroid Injection in Diabetic Patients with Trigger Finger

Baumgarten, Keith M.; Gerlach, David; Boyer, Martin I.

doi:10.2106/jbjs.g.00230

Cited by 99 publications

(26 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, symptom recurrence at 1 year after injection is reported to be 33%–56%,14,44,45 and thus, surgery is often still required. The success rate is further decreased in certain patient groups, such as diabetics 3,44,46. The present study, with a recurrence rate of only 6.1% at 1-year posttreatment, would indicate a better outcome with rESWT than corticosteroid injection and all other conservative methods.…”

Section: Discussionmentioning

confidence: 47%

Radial extracorporeal shockwave therapy for the treatment of finger tenosynovitis (trigger digit)

Malliaropoulos

Jury

Pyne

et al. 2016

OAJSM

View full text Add to dashboard Cite

IntroductionStenosing tenosynovitis that is characterized by the inability to flex the digit smoothly, usually leads to prolonged rehabilitation or surgery.Study designThis case series is a retrospective cohort study.PurposeThe aim of this case series was to evaluate the effectiveness of radial extracorporeal shockwave therapy (rESWT) for the treatment of stenosing tenosynovitis of the digital flexor tendon (trigger digit).MethodsA retrospective analysis of 44 patients (49 fingers) treated with an individually adapted rESWT protocol was conducted. Trigger digit pain and function were evaluated at baseline and 1-, 3-, and 12-months posttreatment. Recurrence and pretreatment symptom duration were analyzed.ResultsSignificant reductions in pain scores and functional improvement were found between baseline and all follow-up assessments (P<0.001). Pretreatment symptom duration was significantly correlated with the number of rESWT sessions required (r=0.776, P<0.001) and 1-year posttreatment pain score (r=0.335, P=0.019).ConclusionThis study provides initial evidence that rESWT is an effective treatment for trigger digit, but randomised controlled trials are required to provide further evidence of this effect.

show abstract

Section: Discussionmentioning

confidence: 47%

Radial extracorporeal shockwave therapy for the treatment of finger tenosynovitis (trigger digit)

Malliaropoulos

Jury

Pyne

et al. 2016

OAJSM

View full text Add to dashboard Cite

show abstract

“…However, some small-scale randomized clinical trials assessing corticosteroid injections vs surgery for trigger finger have been performed. 12,34,35 Findings reveal the superior long-term efficacy of surgery compared with corticosteroid injections. However, corticosteroid injections have a success rate of 50% to 90% depending on the trial.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Surgeon Variation in Adherence to Evidence-Based Recommendations for Treatment of Trigger Finger

et al. 2019

View full text Add to dashboard Cite

show abstract

“…As discussed earlier, individuals with diabetes mellitus have a higher frequency of TF. DM has been established as a bad prognostic factor for medical and surgical interventions in trigger finger [13-14]. Percutaneous release has been reported to be a safe procedure with no to minimum neurovascular damage and very few incidences of infection.…”

Section: Discussionmentioning

confidence: 99%

Outcome of Percutaneous Release for Trigger Digits in Diabetic and Non-diabetic Patients

Siddiqui

Rajput

Adeel

2019

Cureus

View full text Add to dashboard Cite

Introduction Trigger finger (TF) is a common cause of hand pain, swelling, and limited motion. It is common in women and in the thumb. Diabetes mellitus (DM) increases the risk of TF. Individuals with DM who develop TF are resistant to both medical and surgical interventions. The aim of this study is to compare the outcomes of percutaneous trigger release in diabetic and nondiabetic patients. Methods Fifty diabetic and 50 non-diabetic patients with a clinical diagnosis of TF were included after informed consent. Percutaneous trigger release was performed in all of them. Follow-ups for pain and/or neurovascular complications were taken after one week, one month, and six months. Data were entered and analyzed using SPSS v. 22 (IBM Corp., Armonk, NY, US). Results In the diabetic group, 86% of patients had TF of grade III or above and in the non-diabetic group, 76% of patients had TF of grade III or above. At the one-week follow-up, 79.2% diabetic patients still had mild to severe pain and 60.4% non-diabetic patients had mild to severe pain. By one month, 40% patients in the diabetic group still reported mild to moderate pain, however, all patients in the non-diabetic group reported no pain. By six months, nine (20%) diabetic patients reported mild pain. There was no incidence of infection or neurovascular damage at any follow-up in the non-diabetic group, and in the diabetic group, 4.2% of patients had an infection on the one-week follow-up. Conclusion Percutaneous trigger finger release is a safe, reliable, time-saving, and cost-effective procedure for the management of trigger finger in both diabetic and non-diabetic patients.

show abstract

Corticosteroid Injection in Diabetic Patients with Trigger Finger

Cited by 99 publications

References 11 publications

Radial extracorporeal shockwave therapy for the treatment of finger tenosynovitis (trigger digit)

Radial extracorporeal shockwave therapy for the treatment of finger tenosynovitis (trigger digit)

Assessment of Surgeon Variation in Adherence to Evidence-Based Recommendations for Treatment of Trigger Finger

Outcome of Percutaneous Release for Trigger Digits in Diabetic and Non-diabetic Patients

Contact Info

Product

Resources

About